Husband successfully had Lut-177 in 2019 with the vision trial. This June he was fortunately allowed to repeat this treatment, now called Pluvicto. He had all PSMA tumors and the scan showed high expression. By the 2nd treatment the PSA dropped from 15 to 7. We were very happy and post scans showed great uptake. But by the 3rd treatment PSA hadn't changed and by the 4th it started to go back up. Choline petscan was then ordered and they found some mets worsening and now new non PSMA mets were discovered.
Why didn't it work this time? Why did the new mets become non psma? We may never know. So much to learn and research. But thankful for the opportunity to try again.
What was different this time? He wasn't on Xtandi and he started a bone enhancer over a year agovcalled Xgeva. Could this have made a difference, more research and time will help the next guy some day. Still thankful for the bonus years the 1st round gave my husband.
Not without hope though. His Dr repeated the Guardant test many times and in June it came back with High Tumor mutation. This opened up the qualification for immunotherapy. So, he will start Keytruda on Monday.
Carry on my friends in the fight!!!
CJ
Written by
CJ4J
To view profiles and participate in discussions please or .
Please keep us updated on how the Keytruda goes. DH begins Pluvicto on December 21. Hoping for as good a response as your husband had. So glad you still have options. Wishing you the best. Even with your problems, you’ve spread some hope tonight. Thank you.
But, what if it was the Xtandi working alone and not Lut-177 when he had it the first time? Still so much to learn and prove.
Note he did have great response and uptake on the 1st 2 Pluvicto treatments. But, when it mutated, they became non PSMA tumors and the Pluvicto wouldn't have worked on them.
Your husband did not respond to Pluvicto. However, there are a few PSMA negative patients who respond to Pluvicto. Here is a case of a patient with PSMA negative mets. Since the doctors saw no alternatives any more they treated him with Lu177. He had a great response. The remaining met in the red circle was treated with EBRT after the Lu177 therapy. He is in remission for a year now.
Case study of a patient with PSMA negative mets responding to Lu177 therapy.
This is a screenshot of a slide presented at a nuclear medicine conference. This shows an interesting exception. Following that the speaker presented his study showing that mets with missing or low PSMA expression result in a poor prognosis. In particular when there are liver mets.
It is not for the lack of enzalutamide. Pluvicto only targets The PSMA avid cancer. Now non-PSMA metastasis have thrived. So nothing more to be gained with it. Good luck with the Keytruda. Nice to have the plans B, C etc to keep up the fight. We always have to change things up with this wiley disease.
There are targets beyond PSMA, such that PSMA-neg can be treated (in theory). Here’s an article discussing both the copper-based imaging and targeting agents, which target the gastrin-releasing peptide receptor (GRPr):
Thank you lokibear0803, this was mentioned by Dr. Nordquists nurse about a year ago when my husband got follow up calls from the Vision trial. Glad to see it's come to the trial stage. My husband blood counts won't qualify at this time. So, hopefully Keytruda will give him some healing and this could be another card to play later.
Content on HealthUnlocked does not replace the relationship between you and doctors or other healthcare professionals nor the advice you receive from them.
Never delay seeking advice or dialling emergency services because of something that you have read on HealthUnlocked.
Pluvicto 
Enzalutamide and Pluvicto
Docetaxil first, then Pluvicto or Pluvicto first
Is Pluvicto worth pursuing?
Pluvicto with low PSA?
